{"id":759,"date":"2019-09-26T16:49:22","date_gmt":"2019-09-26T07:49:22","guid":{"rendered":"http:\/\/ksilawpat.jp\/?post_type=updates&amp;p=759"},"modified":"2019-09-26T16:49:22","modified_gmt":"2019-09-26T07:49:22","slug":"antigen-binding-molecule-capable-of-binding-to-two-or-more-antigen-molecules-repeatedly","status":"publish","type":"updates","link":"http:\/\/ksilawpat.jp\/updates\/759\/","title":{"rendered":"ANTIGEN-BINDING MOLECULE CAPABLE OF BINDING TO TWO OR MORE ANTIGEN MOLECULES REPEATEDLY"},"content":{"rendered":"<p>[Title of the patent] \u201cANTIGEN-BINDING MOLECULE CAPABLE OF BINDING TO TWO OR MORE ANTIGEN MOLECULES REPEATEDLY\u201d<\/p>\n<p>[Key issue] Enablement requirement (Article 36, paragraph (4), item (i) of the Patent Act)<\/p>\n<p>Court stated in the decision that &#8220;it cannot be said that the Detailed Description of the Invention provides a description to the extent that allows a person ordinarily skilled in the art to implement the whole range of pharmaceutical composition encompassed by the invention.&#8221;<\/p>\n","protected":false},"featured_media":0,"template":"","updates_tag":[3],"class_list":["post-759","updates","type-updates","status-publish","hentry","updates_tag-court-judgment"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"http:\/\/ksilawpat.jp\/index.php\/wp-json\/wp\/v2\/updates\/759","targetHints":{"allow":["GET"]}}],"collection":[{"href":"http:\/\/ksilawpat.jp\/index.php\/wp-json\/wp\/v2\/updates"}],"about":[{"href":"http:\/\/ksilawpat.jp\/index.php\/wp-json\/wp\/v2\/types\/updates"}],"wp:attachment":[{"href":"http:\/\/ksilawpat.jp\/index.php\/wp-json\/wp\/v2\/media?parent=759"}],"wp:term":[{"taxonomy":"updates_tag","embeddable":true,"href":"http:\/\/ksilawpat.jp\/index.php\/wp-json\/wp\/v2\/updates_tag?post=759"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}